Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $77.8 million.

  • vTv Therapeutics' Cash from Financing Activities rose 305891.19% to $77.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.8 million, marking a year-over-year increase of 4861.35%. This contributed to the annual value of $52.6 million for FY2024, which is 33850.13% up from last year.
  • According to the latest figures from Q3 2025, vTv Therapeutics' Cash from Financing Activities is $77.8 million, which was up 305891.19% from -$42000.0 recorded in Q2 2025.
  • vTv Therapeutics' Cash from Financing Activities' 5-year high stood at $77.8 million during Q3 2025, with a 5-year trough of -$282000.0 in Q4 2023.
  • For the 5-year period, vTv Therapeutics' Cash from Financing Activities averaged around $12.3 million, with its median value being $5.0 million (2022).
  • The largest annual percentage gain for vTv Therapeutics' Cash from Financing Activities in the last 5 years was 471171.88% (2023), contrasted with its biggest fall of 10769.02% (2023).
  • Quarter analysis of 5 years shows vTv Therapeutics' Cash from Financing Activities stood at $266000.0 in 2021, then skyrocketed by 1278.57% to $3.7 million in 2022, then crashed by 107.69% to -$282000.0 in 2023, then soared by 973.4% to $2.5 million in 2024, then skyrocketed by 3058.91% to $77.8 million in 2025.
  • Its Cash from Financing Activities was $77.8 million in Q3 2025, compared to -$42000.0 in Q2 2025 and $2.5 million in Q3 2024.